The treatment of multiple sclerosis has made enormous progress thanks to highly effective disease-modifying therapies, in particular anti-CD20 antibodies. For most newly diagnosed patients, a life without disability is realistic. However, the focus is now shifting from preventing acute relapses to combating the insidious progression of disability. New approaches target cellular mechanisms in the CNS and the promotion of remyelination.
Autoren
- Dr. Ulf Blanke
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
You May Also Like
- From diagnostics to personalized therapy
Nuclear medical imaging for Parkinson’s disease
- Psoriasis in difficult localizations: Nail psoriasis
IL-23 and IL-17 as a target – selected study findings
- Artificial intelligence in diabetes prevention
Lifestyle interventions are better accepted with AI
- B-cell lymphomas
Bispecific antibodies – mechanisms, evidence and future role
- Dermatoscopic findings of granulomatous diseases
Cutaneous sarcoidosis, necrobiosis lipoidica and granuloma anulare
- Clostridioides difficile infection: specific therapy
Importance of vancomycin and fidaxomicin has increased
- Study report
Asthma exacerbation risk in patients with a psychological comorbidity
- Neuropathies - CIDP